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Abstract
Background: The increasing problem of infections due to multidrug-resistant Gram-negative
bacteria has led to re-use of polymyxins in several countries. However, there are already clinical
isolates of Gram-negative bacteria that are resistant to all available antibiotics, including polymyxins.
Methods: We present a case series of patients with infections due to pathogens resistant to all
antimicrobial agents tested, including polymyxins. An isolate was defined as pandrug-resistant
(PDR) if it exhibited resistance to all 7 anti-pseudomonal antimicrobial agents, i.e. antipseudomonal
penicillins, cephalosporins, carbapenems, monobactams, quinolones, aminoglycosides, and
polymyxins.
Results: Clinical cure of the infection due to pandrug-resistant (PDR) Gram-negative bacteria,
namely Pseudomonas aeruginosa or Klebsiella pneumoniae was observed in 4 out of 6 patients with
combination of colistin and beta lactam antibiotics.
Conclusion: Colistin, in combination with beta lactam antibiotics, may be a useful agent for the
management of pandrug-resistant Gram-negative bacterial infections. The re-use of polymyxins, an
old class of antibiotics, should be done with caution in an attempt to delay the rate of development
of pandrug-resistant Gram-negative bacterial infections.
Background
The incidence of multiresistant bacterial infections
increases worldwide. This made the medical community
to re-evaluate older agents such as colistin, for infections
due to Gram-negative multiresistant bacteria, including
Pseudomonas aeruginosa, Klebsiella pneumoniae, and Acineto-
bacter baumannii. Colistin was used for about two decades
after its discovery in 1950, but the reported nephrotoxicity
and neurotoxicity led to gradual decrease of its use. How-
ever, the antibiotic recently regained some popularity in
several countries as a salvage antimicrobial agent against
bacteria resistant to all other classes of antibiotics. Fortu-
nately, several studies during the last five years did not
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in the old literature [1,2].
The reuse of colistin is associated with a possible signifi-
cant therapeutical problem, namely the advent of bacteria
resistant to all classes of available antimicrobial agents,
including the polymyxins. These bacteria are really pan-
drug-resistant. It should be noted that the definition of
pandrug-resistant Gram-negative bacteria does not
include always testing for colistin in many countries. For
example, a high mortality rate (60%) was reported in a
study of Acinetobacter baumannii infections from Taiwan;
however, no colistin was used in the in vitro susceptibility
testing and, most important, the drug was not given to
patients [3,4]. There are recent reports from patients with
cystic fibrosis with pandrug-resistant Gram-negative bac-
terial infections [5,6]. In addition, microbiological data
about clinical isolates of Gram-negative bacteria resistant
to colistin were included in some recent reports [7-12].
However, no study up to now has presented the character-
istics of such patients, clinical information about the
infections as well as the outcomes. The objective of this
study was to present data regarding the clinical character-
istics, therapeutic management, and clinical outcome of a
group of patients with infections caused by pandrug-
resistant (PDR) Gram-negative microorganisms.
Methods
Design of the study – data collection
Patients with infections caused by pandrug-resistant
Gram-negative bacteria (resistant to all tested antibiotics,
including colistin), who were hospitalized in the intensive
care unit, during the period from 1/October/2000 to 31/
August/2004 (hospital 1) were identified by the ICU's
electronic database, and during the same period in hospi-
tal 2. The medical records of these patients were reviewed.
Data for several variables, including demographic and
clinical information, as well as results of laboratory and
imaging tests of the patients were collected using a spe-
cially designed case report form and entered in a compu-
ter database.
Definitions
Multidrug-resistant (MDR) Acinetobacter baumannii, Pseu-
domonas aeruginosa, or Klebsiella pneumoniae strains were
defined if resistance of the isolates was observed to 5 out
of the 7 anti-pseudomonal classes of antimicrobial agents,
i.e. antipseudomonal penicillins, cephalosporins, carbap-
enems, monobactams, quinolones, aminoglycosides, and
colistin. Clinically important subsets of MDR Gram-nega-
tive isolates are those sensitive only to colistin and carbap-
enems (CCOS-colistin-carbapenem-only-sensitive). An
isolate was defined as colistin-only-sensitive (COS) if it
was resistant to all anti-pseudomonal agents, except colis-
tin, and as PDR if it exhibited resistant to all 7 anti-pseu-
domonal antimicrobial agents, including colistin.
Intermediate sensitivity was considered as resistance.
The definition of the site of the infection and of the
responsible pathogen were based on the clinical symp-
toms and signs of individual patients, imaging findings,
and on the isolation of a possible pathogen from evalua-
ble clinical specimens. Specifically, diagnosis of pneumo-
nia required two or more serial chest radiographs with at
least one of the following: new or progressive and persist-
ent infiltrate, consolidation, cavitation, or pleural effu-
sion. In addition, patients must have had fever >38°C
with no other recognized cause, or abnormal white blood
cell count [leukopenia (< 4000 WBC/mm3) or leukocyto-
sis (≥ 12.000 WBC/mm3)], and at least two of the follow-
ing: new onset of purulent sputum or change in character
of sputum, increased respiratory secretions or increased
suctioning requirements, new onset or worsening of
cough or dyspnea or tachypnea, rales or bronchial breath
sounds, or worsening gas exchange [13].
Bacteremia required either growth of a recognized patho-
gen from one or more blood specimen cultures or at least
one of the following signs or symptoms: fever (>38°C),
chills, or hypotension and at least one of the following: a)
common skin contaminant (e.g., diphtheroids, Bacillus
sp., Propionibacterium sp., coagulase-negative staphyloco-
cci, or micrococci) grown from two or more blood cul-
tures drawn on separate occasions or b) common skin
contaminant (e.g., diphtheroids, Bacillus sp., Propionibac-
terium sp., coagulase-negative staphylococci, or micro-
cocci) grown from at least one blood culture from a
patient with an intravascular line and physician- insti-
tuted antimicrobial therapy [13].
Infections at other body sites or fluids, such as urinary
tract infections, meningitis, and central venous catheter-
related infections were defined based on guidelines from
the Centers for Disease Control and Prevention [13].
Microbiological testing
Identification of all causative microorganisms was per-
formed by classic microbiologic methods. Susceptibility
testing was performed both by the disk diffusion method
and according to an automated broth microdilution
method (bioMerieux, Vitek II, Hazelwood, MO). The
breakpoints were those defined by the Clinical and Labo-
ratory Standards Institute (CLSI) [14]. The MIC break-
point used to identify bacteria susceptible to colistin was
2 mg/l. Bacteria for which MIC was 2 mg/l or less were
considered susceptible while bacteria with MIC 4 mg/l or
more were considered resistant. Susceptibility to colistin
was tested by means of the disk diffusion method with the
use of 10 µg of colistin sulfate disk (Oxoid, Basingstoke,
Hants, England). Isolates were considered sensitive if thePage 2 of 7
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ified by the E-test technique using the same cut points to
determine the resistant isolates (sensitive: 2 mg/l or less,
resistant: 4 mg/l or more). No molecular biology testing
was performed to clarify whether isolates of the same
microbial species represented the same or different
strains.
Results
Seven patients were identified to have infection due to
pandrug-resistant Gram-negative bacteria during the
study periods. The isolated organisms were found to be
resistant to the following antibiotics; amikacin, aztre-
onam, cefepime, ceftazidime, ciprofloxacin, gentamicin,
imipenem, meropenem, netilmicin, pefloxacin, piperacil-
lin/tazobactam, ticarcillin/clavulanic acid, trimethoprim/
sulfamethoxazole, cefpirome, colistin, and isepamicin.
The clinical features of patients, including the isolated
pandrug-resistant strains, the antimicrobial agents used
for the management of the infections, as well as their out-
come, are shown in the table. The colistin formulation
that was administered to the patients was sodium colis-
timethate (Colomycin, Forest Laboratories®, Kent, UK).
One milligram of the colistin used is approximately equal
to 12,500 IU. Other data related to the hospitalization of
these patients are summarized below.
Patient 1
A 47-year-old male was transferred from another ICU due
to multiple chest injuries after a car accident, respiratory
tract infection, and ICU polyneuropathy. Based on clini-
cal and microbiological evidence, therapy for severe pneu-
monia was initiated on the 2nd day of the ICU stay, with a
combination of imipenem/cilastatin, gentamicin,
ofloxacin and vancomycin that were given for 10, 22, 6
and 14 days respectively. Imipenem/cilastatin was substi-
tuted with piperacillin/tazobactam given for 12 days, and
piperacillin/tazobactam was then substituted with ceftri-
axone given for 10 days. On the 30th day teicoplanin was
added to the regimen, given for 21 days. On the 40th day
of the ICU stay, a PDR Pseudomonas aeruginosa strain was
isolated from his bronchial secretions. He was subse-
quently treated, due to the persistence of the infection,
with a prolonged course of intravenous colistin for a total
of 52 days, combined with imipenem/cilastatin for 12
days, then meropenem for 23 days and then ofloxacin for
16 days. On the 54th day a strain of Pseudomonas aeruginosa
sensitive only to colistin (COS) was isolated from his
bronchial secretions. The infection was gradually control-
led and, finally, the patient was discharged from the hos-
pital in a good condition.
Patient 2
A 47-year-old female was admitted to the ICU due to pos-
sible meningitis. She had been operated for meningioma
and had a ventriculo-peritoneal shunt. The shunt was
removed at the day of admission with simultaneous inser-
tion of external cerebrospinal fluid drainage. The initial
cultures of CSF specimens were negative. The patient was
treated with intravenous ceftriaxone and vancomycin. A
CSF specimen, taken on the 24th day of ICU stay, grew a
MDR Pseudomonas aeruginosa strain (sensitive only to col-
istin and piperacillin/tazobactam, intermediate sensitive
to imipenem and meropenem) and ceftriaxone was sub-
stituted with piperacillin/tazobactam and meropenem.
Due to deterioration of her clinical condition several com-
binations of antimicrobial agents were subsequently
given, including ciprofloxacin for 19 days, chloramphen-
icol for 11 days, colistin for 23 days, and gentamicin for 6
days. On the 62nd day of the ICU stay, a PDR Pseudomonas
aeruginosa strain was isolated from a cerebrospinal fluid
specimen. Until the isolation of the PDR strain, repeated
CSF specimen cultures grew MDR Pseudomonas aeruginosa.
A gradual change in the Pseudomonas susceptibility was
observed from multidrug-resistance to pandrug-resist-
ance. The patient died on the 66th day of hospitalisation
due to Pseudomonas meningitis.
Patient 3
An 18-year-old male was admitted to the ICU with frac-
tures of the 2nd and 3rd cervical vertebrae and concomitant
acute respiratory failure type I. Pneumonia was diagnosed
clinically and confirmed microbiologically. Staphylococcus
aureus and COS Acinetobacter baumannii were repeatedly
isolated from bronchial secretions during the second and
the third week of his hospitalization, respectively. Differ-
ent combinations of antibiotics were provided, due to the
persistence of severe pneumonia. The antibiotics were
vancomycin, broad-spectrum cephalosporins, clindamy-
cin, piperacillin/tazobactam, aminoglycosides, quinolo-
nes, meropenem and colistin (given for a total of 21, 15,
9, 7, 25, 7, 6 and 11 days respectively, up to the 34th day
of ICU stay). On the 34th day of ICU stay PDR Pseu-
domonas aeruginosa grew from his bronchial secretions. At
that time, he was receiving colistin, meropenem,
ofloxacin and gentamicin. He continued to receive the
same antimicrobial combination. PDR Pseudomonas aeru-
ginosa was not isolated again from subsequent cultures of
bronchial secretions. Instead, Acinetobacter baumannii
grew again from bronchial secretions on the 35th day of
hospitalization and in subsequent cultures by the 45th day
of ICU stay. Meanwhile a gradual improvement of the
infection was noted. The patient was transferred to a spe-
cialized orthopedic center after 78 days of ICU stay, in
good general condition, without evidence of pneumonia
or other infection.
Patient 4
A 72-year-old female was admitted to the ICU with a com-
plicated, severe urinary tract infection (UTI) due to COSPage 3 of 7
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drome (ARDS). During the last trimester, she had been
hospitalized twice for episodes of UTIs. Treatment with
intravenous colistin and meropenem was initiated on ICU
admission and 15 days later urine specimen cultures were
negative. However, due to persistence of fever the treat-
ment was continued. Vancomycin was added to the regi-
men after isolation of Enterococcus faecium from cultures
of the tip of the central venous catheter (CVC) on the 8th
day of ICU stay. On the 33rd day, PDR Klebsiella pneumo-
niae was isolated from the tip of the CVC. Due to unavail-
ability of antimicrobial agents with in vitro effect against
the pathogen, no change in the antimicrobial regimen was
performed. Her clinical condition was complicated on the
37th day with lower respiratory tract infection and bacter-
emia due to COS Pseudomonas aeruginosa, for which a
short course of gentamicin was added to the treatment.
From the tip of the CVC, MDR Klebsiella pneumoniae resist-
ant to all tested drugs (not tested for colistin) was isolated
again on the 48th day, and COS Klebsiella pneumoniae on
the 63rd day of ICU stay. Her clinical condition improved
gradually, although COS Pseudomonas aeruginosa kept
being isolated in cultures of bronchial secretions up to the
78th day of ICU stay. She was transferred in good condi-
tion to another hospital for continuation of her care, with-
out fever or other clinical and laboratory evidence of
infection, after 85 days of ICU stay.
Patient 5
A 56-year-old male was admitted to the ICU after elective
operation for a thoraco-abdominal aortic aneurysm and
intra-operative hemorrhage. On the 24th day of ICU stay
the patient was re-operated for infection of the thoracot-
omy with pus collection, which required drainage. On the
52nd day PDR Klebsiella pneumoniae was isolated from
bronchial secretions. He had already received 31 days of
colistin treatment, combined with ampicillin/sulbactam
(for 22 days) and trimethoprim/sulphamethoxazole (for
8 days), all given for treatment of polymicrobial pneumo-
nia caused by MDR strains of Acinetobacter baumannii and
Klebsiella pneumoniae and bacteremia by MDR Klebsiella
pneumoniae strain. By the time of isolation of the PDR
microorganism the patient's condition was steadily dete-
riorating; eventually irreversible septic shock and multiple
organ failure led to his death on the 68th day of ICU stay.
Patient 6
A 35-year-old male was transferred to our hospital from
another medical center with infection of the lower respi-
ratory tract and UTI due to COS Pseudomonas aeruginosa.
The patient had a history of rupture of an aneurysm of the
circle of Willis that was surgically managed. During his
prolonged hospitalization, episodes of obstructive hydro-
cephalus and CNS infection complicated his clinical con-
dition, which necessitated admission to the ICU. On the
32nd day of ICU stay, PDR Pseudomonas aeruginosa was iso-
lated from a urine specimen. By that time, he had received
several combinations of antimicrobial agents, including 6
days of treatment with colistin, for lower respiratory tract
infection with COS Pseudomonas aeruginosa. After isola-
tion of the PDR pathogen he received combination treat-
ment with colistin and ceftazidime leading to clinical cure
of the UTI. The clinical condition of the patient gradually
improved and he became afebrile. However, the patient's
respiratory tract remained constantly colonized with MDR
and COS Pseudomonas aeruginosa strains. He was trans-
ferred to the neurosurgical ward after 134 days of ICU
stay, in improved condition. Thirty days later, pneumonia
relapsed and progressed into septic shock and multiple
organ failure, and subsequent death.
Patient 7
An 82-year-old male was admitted in the nephrology
clinic due to cellulitis of the right lower limb. The patient
had a history of chronic renal failure and a recent episode
of bronchiolitis obliterans organizing pneumonia
(BOOP). Blood specimen cultures performed on admis-
sion and 24 hours later, grew both PDR Pseudomonas aer-
uginosa strain. Treatment with intravenous piperacillin/
tazobactam was initiated. A quick improvement of the cel-
lulitis was noted. The therapeutic regimen was not
changed when a result for isolation of a PDR Pseudomonas
aeruginosa strain from the blood cultures became availa-
ble. The patient was discharged to home after 10 days of
treatment, with the cellulitis cured. In addition, subse-
quent blood cultures did not reveal any isolates.
Discussion
We present the first case series that focuses on clinical
information and outcome of infections due to pandrug-
resistant Gram-negative bacteria. Our study shows that
the isolation of a pandrug-resistant Gram-negative rod
from clinical specimens does not necessarily mean a bad
outcome. This may be explained by several reasons. First,
the achieved concentration of several antimicrobial agents
in some body fluids, including the urine may exceed the
minimal inhibitory concentration of the isolated patho-
gen, even if the in vitro susceptibility result would place
the isolate in the resistant category. Second, infections,
even severe, sometimes are self-limited without the use of
antimicrobial agents, as the pre-antibiotic era taught us.
Third, pandrug-resistant bacteria may be colonizers of the
respiratory tract in patients receiving several classes of
antimicrobial agents for a long period of time, while the
real pathogen may not be isolated. Fourth, it has been
shown that occasionally MDR organisms may exhibit
decreased virulence compared to other more sensitive
organisms of the same species.Page 4 of 7
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of colistin with antimicrobial agents such as carbapen-
ems, third generation cephalosporins, and quinolones.
This fact represents an important practical observation of
our study. Specifically, 4 patients achieved complete cure
from the pandrug-resistant Gram-negative bacterial infec-
tion, with combinations of colistin with other antimicro-
bial agents, with which may have a synergistic effect.
Previous experimental and clinical studies showed prom-
ising results regarding the synergistic effect of colistin with
antibiotics from other classes such as β-lactams (piperacil-
lin, ceftazidime, aztreonam, meropenem), aminoglyco-
sides (amikacin, gentamicin), sulfonamides
(trimethoprim/sulfamethoxazole), rifamycins
(rifampicin), and quinolones (ciprofloxacin) against
MDR Gram-negative bacteria [15-17]. However, clinical
trials are needed to evaluate the in vivo results of these
combinations.
Colistin resistance among Gram-negative organisms has
been reported up today in some in vitro studies, as well as
in surveillance studies for antimicrobial resistance
[7,8,18]. In most of these studies the isolated strains of
Pseudomonas aeruginosa, Klebsiella pneumoniae, and Acineto-
bacter baumannii exhibited a greater than 98% susceptibil-
ity to colistin or polymyxin B. However, reports about
clinical parameters and outcome of infections due to col-
istin-resistant Gram-negative bacteria are rare in the liter-
ature. A search of PubMed and Current Contents
databases revealed only 2 such reports. Both of them
referred to cystic fibrosis patients [5,6]. In the first study,
5 out of 44 adult patients with cystic fibrosis and Pseu-
domonas aeruginosa chronic bronchial infection developed
resistance to colistin. In the second study, colistin resistant
Pseudomonas aeruginosa was found in 5 out of 150 children
with cystic fibrosis over a 5-year period of follow up. Our
study confirms the rarity in the incidence of such infec-
tions since in a study period of several years we recorded
only seven such infections in two hospitals.
Gram-negative bacteria can develop resistance to poly-
myxins through mutation or adaptation mechanisms
[19]. Mutation is inherited, low-level, and independent of
the continuous presence of the antibiotic, whereas adap-
tation is the opposite (non-inherited, high level, and
requires the continuous presence of the antibiotic).
Almost complete cross-resistance exists between colistin
and polymyxin B [20,21]. It has been suggested that a
basic mechanism of resistance in Pseudomonas aeruginosa
strains is that the outer membrane protein OprH blocks
the self-promoted uptake pathway of polymyxins by
replacing Mg2+ on the LPS molecule. Thus, the overexpres-
sion of OprH caused by mutation or as a result of adapta-
tion to an Mg2+-deficient medium can be associated with
resistance to polymyxins [22,23].
Studies on polymyxin-resistant Pseudomonas aeruginosa
strains have suggested that cell surface changes are related
with the development of resistance. These include altera-
tions of the outer membrane of the bacteria cell (reduc-
tion of LPS, reduced levels of specific outer membrane
proteins, reduction in cell envelope Mg2+ and Ca2+ con-
tents, and lipid alterations). Specifically, the absence of 2-
hydroxylaurate, the presence of 4-aminoarabinose, and
increase in the palmitate content of lipid A has been asso-
ciated with resistance of Pseudomonas aeruginosa to poly-
myxins [5,24]. In addition, studies in Salmonella spp. have
shown that the two component systems PhoP-PhoQ and
PmrA-PmrB regulate polymyxin resistance. The transcrip-
tion of PmrA-PmrB is activated by the PhoP-PhoQ or by
growth in mild acidic conditions (pH = 5.8) and micro-
molar concentrations of Mg2+ (10 µM). The products of
PmrA-PmrB activated genes are responsible for the modi-
fications on the LPS molecules of Gram-negative bacteria.
Consequently, the affinity of polymyxins to the bacterial
cell surface is reduced [24].
In addition, a recent study in Yersinia spp. demonstrated
that an efflux pump/potassium antiporter system may be
associated with the mediation of resistance to cationic
antimicrobial peptides in general, including polymyxin B
[25]. Although enzymatic resistance of bacteria to poly-
myxins has not been reported, it is interesting that Bacillus
polymyxa subsp.colistinus produces colistinase that inacti-
vates colistin [26].
Guidelines from Clinical and Laboratory Standards Insti-
tute (CLSI) the about the in vitro determination of the
minimum inhibitory concentrations (MICs) of different
microorganisms to colistin using broth dilution and agar
dilution techniques were established in 1970. However,
due to the rare use of colistin in the United States and
most countries, the CLSI guidelines were not modified
after 1981 and were withdrawn in 2000. The re-use of pol-
ymyxins during the last years will make necessary the re-
evaluation of the susceptibility breakpoints. A common
method for susceptibility testing of colistin has been the
disk diffusion method that uses 10 micrograms of colistin
sulfate disk (Oxoid, Basingstoke, Hants, England). Iso-
lates are considered sensitive if the inhibition zone is ≥ 11
mm. It is important to emphasize that in clinical practice
it is colistimethate sodium, not colistin sulfate that is used
for intravenous administration. There is generally agree-
ment in the results obtained from agar dilution and broth
microdilution methods regarding testing of colistin sul-
fate [27]. However, it has been suggested that the disk dif-
fusion test should be confirmed with a dilution method,
because the disk diffusion method may reveal false-sus-
ceptible microorganisms [27].Page 5 of 7
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First, molecular typing was not performed thus the possi-
bility that PDR isolates derived from the previous isolated
microorganisms cannot be determined. Second, MDR or
PDR bacteria were markers of the patients' condition and
the effect of the infection and of the treatment on the out-
come of the patients cannot be adequately evaluated.
Conclusion
In an era of alarmingly increasing bacterial resistance, our
study adds clinical information about the outcome of
infections due to pandrug-resistant Gram-negative bacte-
ria. Further work is needed to elucidate the possible in
vitro synergistic effect of combinations of colistin with
antibiotics from several classes and their effectiveness in
clinical practice.
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